Lymphoma is cancer of the lymphatic system, divided into Hodgkin and non-Hodgkin types with dozens of subtypes. Many lymphomas are now highly treatable or curable with chemotherapy, immunotherapy, or targeted drugs, though aggressive forms and relapsed disease remain challenging.
What's actually going on in research
Trials are testing CAR T-cell therapy for earlier lines of treatment, bispecific antibodies that redirect immune cells to cancer, next-generation BTK inhibitors for B-cell lymphomas, and antibody-drug conjugates that deliver chemotherapy directly to tumor cells. Researchers are also studying ways to avoid or reduce chemotherapy in people whose lymphomas respond well to newer agents.
CAR T-cell therapy expansion
CAR T-cell therapy, where a person's immune cells are engineered to attack lymphoma, was approved for relapsed disease and is now being tested as earlier treatment. Trials are comparing it to standard chemotherapy combinations to see if it can replace harsher regimens.
Bispecific antibodies
These drugs attach to both a cancer cell and an immune cell, forcing them together so the immune system destroys the tumor. Several bispecifics are FDA-approved for relapsed lymphoma, and trials are testing them in newly diagnosed disease.
Chemotherapy-free regimens
Some lymphomas respond so well to targeted drugs or immunotherapy that trials are testing whether chemotherapy can be skipped entirely. Early results in certain subtypes show similar outcomes with fewer side effects.
What to know before you search
Eligibility typically depends on lymphoma subtype, stage, number of prior treatments, organ function, and sometimes specific genetic markers in the tumor.
What types of trials are currently open
- CAR T-cell trials — Testing engineered immune cells as earlier treatment, in combination with other drugs, or using next-generation CAR T designs with fewer side effects.
- Bispecific antibody trials — Testing drugs that link cancer cells to immune cells, often given as infusions or injections, to see if they work in earlier disease or with fewer treatments.
- Targeted therapy trials — Testing BTK inhibitors, PI3K inhibitors, and other drugs that block specific pathways lymphoma cells need to survive.
- Antibody-drug conjugate trials — Testing antibodies attached to chemotherapy that deliver the drug directly to lymphoma cells, sparing healthy tissue.
- Combination trials — Testing new drugs added to standard chemotherapy, or testing whether chemotherapy can be reduced or eliminated when combined with newer agents.
Recently added Lymphoma trials
Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
This is a study for patients with a type of blood cancer called large B-cell lymphoma (LBCL) who have a mutation in a gene called TP53. This gene mutation often makes the cancer harder to treat with standard therapies. CAR T-cell therapy is a treatment that uses a patient's own immune cells to fight cancer. However, some patients relapse (the cancer comes back) after CAR T-cell therapy. This study will test whether taking two drugs - chidamide (a tablet taken by mouth) and a PD-1 inhibitor (given by intravenous infusion) - as maintenance therapy after CAR T-cell therapy can help keep the cancer from coming back. Participants in this study will receive CAR T-cell therapy, followed by maintenance treatment with chidamide combined with a PD-1 inhibitor. Doctors will closely monitor participants for how well the treatment works and for any side effects. The study will take place at a single hospital, and all participants will receive the same treatment. The main goal of the study is to find out if this maintenance treatment is effective and safe for patients with TP53-mutant large B-cell lymphoma.
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.
Find Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.